Akari Therapeutics Plc【AKTX】
| Dec 31,
2013 | Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net loss | -4 | -10 | -45,317,532 | -18,140,997 | -35,399,257 | -16,466,780 | -17,105,791 | -17,081,617 | -17,424,237 | -17,748,062 | -10 | -20 |
|---|
| Depreciation and amortization | - | - | - | 39,944 | 42,400 | 35,848 | 19,205 | 8,907 | 4,126 | 3,708 | 0 | 0 |
|---|
| Stock-based compensation | 2 | 0 | 1 | 4 | 3 | 2 | 1 | 325,523 | 314,650 | 735,107 | 1 | 2 |
|---|
| Issuance of shares for services | - | - | 750,000 | - | - | - | - | - | - | - | 0 | 0 |
|---|
| Fair Value Adjustment of Warrants | - | - | -11,408,231 | - | - | - | - | - | - | 2 | - | - |
|---|
| Change in fair value of warrant liabilities | - | - | 11 | 9 | 3 | 3 | -60,640 | 556,810 | - | 7 | 7 | 2 |
|---|
| Unrealized foreign currency exchange losses (gains) | - | - | - | - | - | - | - | - | - | - | - | -0 |
|---|
| Foreign currency exchange (gains) losses | - | - | -90,588 | 272,985 | -93,402 | 104,719 | 30,366 | 490,782 | -242,503 | 334,168 | 0 | - |
|---|
| Prepaid expenses and other current assets | - | - | -913,788 | 785,876 | -807,408 | 716,859 | -710,335 | -192,054 | 2 | -1,698,991 | -0 | -1 |
|---|
| Accounts payable and accrued expenses | - | - | 4 | -671,784 | 12,222 | -3,689,860 | 2 | -247,683 | -241,309 | -877,098 | -1 | 5 |
|---|
| Net cash used in operating activities | -5 | -9 | -4,965,583 | - | -31,598,709 | -22,580,240 | -12,918,313 | -16,950,408 | -18,846,528 | -21,504,522 | -16 | -13 |
|---|
| Cash Acquired from Acquisition | - | - | 1 | - | - | - | - | - | - | - | - | 0 |
|---|
| Net cash provided by investing activities | - | -0 | 1 | - | 10 | - | - | - | - | - | - | 0 |
|---|
| Proceeds from Issuance of Common Stock | 0 | - | 75 | - | 17 | 306,232 | 13 | 25 | 14 | 25 | 7 | 12 |
|---|
| Proceeds from Convertible Debt | 1 | - | - | - | - | - | - | - | - | - | - | 1 |
|---|
| Repayment of convertible notes | 1 | - | - | - | - | - | - | - | - | - | - | 1 |
|---|
| Proceeds from issuance of restricted shares | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Proceeds from employee vesting of restricted shares | - | - | - | - | - | - | - | - | - | - | 0 | 0 |
|---|
| Payments on short-term financing arrangement | - | - | - | - | - | - | - | - | - | - | - | 1 |
|---|
| Proceeds from Warrant Exercises | - | - | - | - | - | - | - | 27,500 | - | - | - | - |
|---|
| Net cash provided by financing activities | 24 | 8 | 69 | - | 16 | 306,232 | 13 | 25 | 14 | 25 | 7 | 11 |
|---|
| Effect of exchange rates on cash | - | - | - | - | - | -6,931 | 34,084 | - | - | 105,088 | 0 | -0 |
|---|
| Net decrease in cash | - | - | - | - | - | -22,280,939 | -236,276 | 8 | -4,694,507 | 4 | -9 | -1 |
|---|
| Financing costs in accounts payable and accrued expenses | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Seller-financed purchases | - | - | - | - | - | - | - | - | - | - | - | 1 |
|---|
| Payroll taxes on stock-based compensation in accrued expenses | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Stock Issued | - | - | - | - | - | - | - | - | - | - | - | 28 |
|---|
| Liabilities Assumed | - | - | - | - | - | - | - | - | - | - | - | 2 |
|---|
| Cash paid for interest | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|